» Articles » PMID: 20465705

Large-scale Worldwide Observational Study of Adherence with Acne Therapy

Overview
Journal Int J Dermatol
Specialty Dermatology
Date 2010 May 15
PMID 20465705
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Acne is a common chronic disease that typically requires prolonged treatment. Several small studies conducted over the past few years suggest that adherence to acne medications is often poor. In addition, data regarding the factors that positively or negatively impact adherence in patients with acne are sparse. This study utilized a simple, validated questionnaire (ECOB, Elaboration d'un outil d'evaluation de l'observance des traitements medicamenteux) to assess the risk of poor adherence in a large worldwide cohort of acne patients (n = 3339) from three major geographic regions [the Americas (n = 952), Europe (n = 1196), and Asia (n = 1191). In addition, information about patient and treatment characteristics was collected to identify factors that correlated with adherence. Overall, there was a poor adherence rate of 50% in this study; this varied by region, with significantly worse adherence in Europe versus Asia and America (poor adherence rates of 58%, 48%, and 43%, respectively, P < 0.0001). To provide insight into factors that affect medication-taking behavior in acne, adherence was analyzed by the type of treatment (a combination of topical and systemic, topical only, oral isotretinoin). Among patients taking a combination of both systemic and topical therapy, 60% (n = 944) of patients had poor adherence to at least one treatment as defined in the study protocol. In this group, there was a higher proportion of patients who had poor adherence to systemic treatment versus topical treatment (54% vs. 44%, respectively). Among patients treated with topical therapy only, poor adherence occurred in 40% (n = 356) of cases. A total of 46% (n = 325) of patients using oral isotretinoin therapy had poor adherence. Multivariate analysis showed that poor adherence was independently correlated with young age (most strongly with <15 years but also in the age group from 15 to 25 years), the occurrence of side effects, lack of improvement as evaluated by dermatologist, previous systemic therapy, lack of knowledge about acne treatment, consultation with a primary care physician, and lack of patient satisfaction with treatment. Factors that had a positive effect on adherence were more severe acne, use of cosmetics (moisturizers, cleansers), use of either topical therapy alone or isotretinoin, good clinical improvement as evaluated by the dermatologist, patient satisfaction with therapy, and knowledge of acne treatment.

Citing Articles

Disease perception, treatment-seeking behaviour and psychosocial impact of acne vulgaris among university students - A cross-sectional study.

Tan Y, Jamil A, Gunabalasingam P Malays Fam Physician. 2025; 20:3.

PMID: 39949652 PMC: 11821277. DOI: 10.51866/oa.622.


A Pilot Study on the Comparative Efficacy and Tolerability of a Novel Dermo-cosmetic Cream with 15% Azelaic Acid for Mild to Moderate Acne: A New Approach to Acne Treatment.

Vladuti A, Hatami A, Clement A, Mainzer C Dermatol Ther (Heidelb). 2024; 14(11):3149-3160.

PMID: 39487327 PMC: 11557742. DOI: 10.1007/s13555-024-01294-x.


Effectiveness and Safety of a Dermocosmetic Cream as an Adjunct to Adapalene for Mild and Moderate Acne in Indonesia: Results of a Multicenter Randomized Controlled Study.

Sitohang I, Norawati L, Yenny S, Kusumawardani A, Murlistyarini S, Setiawan S Clin Cosmet Investig Dermatol. 2024; 17:2283-2296.

PMID: 39430644 PMC: 11490241. DOI: 10.2147/CCID.S474331.


Current Insights on Treatment Adherence in Prevalent Dermatological Conditions and Strategies To Optimize Adherence Rates.

Cirstea N, Radu A, Vesa C, Radu A, Bungau A, Tit D Cureus. 2024; 16(9):e69764.

PMID: 39429316 PMC: 11490752. DOI: 10.7759/cureus.69764.


Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis.

Kircik L, Gold L, Gold M, Weiss J, Harper J, Del Rosso J Dermatol Ther (Heidelb). 2024; 14(5):1211-1227.

PMID: 38724841 PMC: 11116301. DOI: 10.1007/s13555-024-01155-7.